Ignite Creation Date:
2024-05-06 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05231122
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2022-01-24
Brief Title:
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Organization Data
Organization:
Roswell Park Cancer Institute
Class:
OTHER
Study ID:
I 1277721
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Roswell Park Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Celldex Therapeutics | INDUSTRY |
| National Cancer Institute NCI | NIH |
| Merck Sharp Dohme LLC | INDUSTRY |